Beijing Biostar Pharmaceuticals Co., Ltd.

北京華昊中天生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2563)

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025

The board (the "**Board**") of directors (the "**Directors**") of Beijing Biostar Pharmaceuticals Co., Ltd. (the "**Company**") hereby announce the audited consolidated results of the Company and its subsidiaries (collectively, the "**Group**") for the year ended December 31, 2025, along with comparative figures for the year ended December 31, 2024. These annual results have been reviewed by the Audit Committee of the Company and approved by the Board on March 30, 2026.

In this announcement, "we" and "our" refer to the Company, unless otherwise indicated, in which case they refer to the Group. Certain amounts and percentage figures contained in this announcement have been rounded or approximated to one or two decimal places (as applicable). Any differences between the totals and the sum of the amounts shown in any table, chart or elsewhere are due to rounding. Unless otherwise defined, terms used in this announcement have the same meanings as those defined in the Prospectus.

FINANCIAL HIGHLIGHTS

	For the year ended December 31,		
	2025	2024	**YOY**
	RMB'000	*RMB'000*	**CHANGE**
Revenue	**33,364**	71,866	–53.6%
Gross profit	**30,757**	62,121	–50.5%
Net profit	**–131,435**	–143,777	–8.6%
Loss for the year attributable to equity shareholders of the Company	**–131,435**	–143,777	–8.6%
Loss per share	**–0.36**	–0.41	–12.2%
Monetary funds	**456,767**	466,636	–2.1%
R&D expenses	**–82,993**	–116,292	–28.6%

MANAGEMENT DISCUSSION AND ANALYSIS

Business Review

As of the date of this announcement, the Company continued to make significant progress in various areas, including advancement of R&D pipeline, strategic marketing cooperation, publication of academic results, and intellectual property layout, and reached major milestones and made achievements as follows:

1. ***Advancement of R&D pipeline***

We are a synthetic biology-driven biopharmaceutical company committed to developing innovative drugs in oncology. We have successfully developed three core technology platforms which focus on the R&D of microbial metabolite new drugs. As of the end of the current Reporting Period, we had one commercialized product and 19 R&D pipeline projects. Our core product, Utidelone Injection, received approval from the National Medical Products Administration (NMPA) in 2021 for its indication, the treatment of relapsed or metastatic breast cancer patients who have received at least one anthracycline- or taxane-containing chemotherapy regimen in combination with capecitabine. This ended a nearly two-decade absence of independently-developed domestic Class 1 innovative chemotherapy drugs in China. As of the end of the current Reporting Period, Utidelone Injection was the only approved chemotherapy drug developed using synthetic biology technology, and it was also the sole microtubule inhibitor oncology drug with a new molecular structure that has been approved worldwide since 2010.

Given the properties and advantages of Utidelone, such as the ability to cross the blood-brain barrier, broad anti-cancer spectrum, high oral bioavailability, low hematological toxicity and the ability to overcome multidrug resistance mechanisms, during the current Reporting Period, we vigorously made arrangements for the expansion of new indications of Utidelone, the clinical development of its oral formulation and other aspects both domestically and internationally. For Utidelone Injection, two pivotal registrational clinical trials for breast cancer and lung cancer brain metastasis have been commenced in the U.S. and China respectively with positive progress. We have completed the phase II clinical study for solid tumors, and obtained promising clinical data in, among other cancers, gastric and esophageal cancers. Such data will guide our phase Ⅲ studies at a later stage. Meanwhile, we have deployed new R&D pipelines, including the phase II clinical study for the first-line treatment of advanced pancreatic cancer. Such indication was granted orphan drug designation by U.S. Food and Drug Administration (FDA). For the Utidelone Capsule, we have successfully completed the phase I clinical study in China and the U.S., which has shown good efficacy and safety profile along with high oral bioavailability. The Phase II clinical study of Utidelone Capsule in combination with capecitabine for the treatment of advanced breast cancer in China has been successfully completed. The results demonstrate that, compared with Utidelone Injection, the capsule formulation achieves comparable or even superior efficacy benefits in terms of progression-free survival (PFS), objective response rate (ORR), and other key endpoints. On the safety profile, it significantly reduces the incidence and severity of peripheral neurotoxicity which is a characteristic adverse effect of microtubule inhibitors and certain other chemotherapeutic

agents, lowering the rate of Grade 3 peripheral neuropathy from 25.1% to 2%, with no cases of Grade 4 peripheral neuropathy observed. Meanwhile, it fully preserves Utidelone's well-established advantage of low hematological toxicity. Utidelone Capsule represents an innovative, domestically developed modified new drug in China and marks the world's first solid oral formulation of a microtubule-stabilizing agent. We are of the view that Utidelone Capsule represents an enhancement in cancer treatments, as it provides more convenience and better compliance from patients, eases the financial burden on patients, and could facilitate combination with other anti-cancer drugs to open up opportunities for new therapies. Therefore, the Company has exerted much effort in the subsequent phase II/III clinical pipeline of Utidelone Capsule, including the phase III clinical study for strengthened triple-negative breast cancer (TNBC) adjuvant treatment, the phase II/III international multi-center clinical study for advanced gastric cancer, the phase II/III international multi-center clinical study for advanced ovarian cancer and other large studies with enrollment underway.

Meanwhile, the Company is actively building a next-generation antibody-drug conjugate (ADC) technology platform with fully independent intellectual property rights. This platform focuses on systematic innovation around two core elements: a differentiated payload system and linkers. Unlike prevailing ADC products that commonly use widely adopted payloads such as monomethyl auristatin E (MMAE) or topoisomerase I (Topo I) inhibitors, this platform innovatively employs the Company's proprietary synthetic biology-derived product Utidelone and other epothilone derivatives as the core toxin molecules, which can be selectively combined with Topo I inhibitors to develop dual-payload or multi-payload ADC drugs. Utidelone and other epothilone derivative payloads belong to the class of epothilone-based microtubule-stabilizing agents. They exhibit potent antitumor activity, excellent cell membrane permeability, potential to overcome P-glycoprotein (P-gp)-mediated multidrug resistance in tumor cells, a well-defined mechanism of action, and a favorable safety profile, conferring significant differentiated competitive advantages in the ADC field. Preclinical studies are currently advancing vigorously, with the goal of reaching the investigational new drug (IND) enabling stage in 2026.

As of the end of the Reporting Period, the latest R&D pipeline chart of the Company is as follows (note: the pipeline chart excludes certain completed studies or investigator-initiated trials (IITs)):



Utidelone Injection

- Phase III clinical trial of Utidelone Injection for HER2- breast cancer neoadjuvant therapy

  This study is a superiority design with head-to-head comparison against docetaxel. Anthracycline (AC) in combination with taxanes is currently a standard neoadjuvant treatment for patients with HER2- breast cancers, nevertheless its efficacy and safety profile are limited. Based on the background that Utidelone Injection was approved for the treatment of advanced breast cancer, we believe that it can be applied to early breast cancer treatment and can benefit more cancer patients, meanwhile expanding our market share. As of the end of the Reporting Period, we have enrolled nearly 90% of the target number of patients, and the incidence rate of collected adverse events was low, and these adverse events were easily manageable, indicating good safety profile of Utidelone Injection in combination with AC. Efficacy data will be obtained after reaching a sufficient number of evaluable cases and completing statistical analysis. All patients are expected to be enrolled by mid-2026. We believe that our product has the potential to become a preferred neoadjuvant chemotherapy option for HER2- breast cancer (particularly the TNBC).

- Phase II clinical trial of Utidelone Injection for solid tumors (in combination with PD-1 for the first-line treatment of advanced gastric and esophageal cancers) in China (completed)

  According to the data of the first stage of the phase II clinical trial, the CBR of Utidelone monotherapy for advanced gastric cancers (GC) and esophageal cancers (ESCC) reached 53% and 70%, with ORR of 20% and 40%, respectively. Hence, we conducted the second-stage study of Utidelone in combination with PD-1 for the first-line treatment of GC and ESCC, and completed this study during the Reporting Period. Utidelone plus PD-1 inhibitor and chemotherapy demonstrated promising efficacy and acceptable safety as first-line treatment for GC and ESCC. There were 27 eligible patients enrolled in the GC cohort and 23 patients were evaluable for efficacy. 5 patients were still receiving treatment (up to 23 cycles). The ORR was 65.2% and CBR was 100%. The mPFS was >6.1 months. There were 20 eligible patients enrolled in the ESCC cohort and 18 patients were evaluable for efficacy. 6 patients were still receiving treatments (up to 12 cycles). The ORR was 33.3% and CBR was 100%. The safety profiles were good for both cohorts, with no treatment-related deaths. Latest study findings have been presented as a poster at the 2025 American Society of Clinical Oncology (ASCO) annual meeting.

- Phase II clinical trial of Utidelone Injection in combination with bevacizumab for HER2 negative breast cancer with brain metastasis (investigator-initiated trial)

  The results of this clinical trial were published in the JAMA Oncology during the Reporting Period. Utidelone can cross blood-brain barrier, enabling it to reach a high drug concentration in brain tissues, thereby playing a role in preventing and treating brain metastases. The primary objective of this study was to investigate the efficacy and safety of Utidelone combined with bevacizumab in the treatment of advanced breast cancer brain metastases. From May 5, 2022 to October 25, 2023, a total of 47 patients were recruited. Among them, 35 patients had untreated CNS lesions, while 12 had progressive brain metastases after local radiotherapy. In terms of safety profile, the most common grade 1-2 adverse events (AEs) were peripheral neuropathy, decreased neutrophil count, etc. No grade 3 or higher treatment-related AEs occurred. Regarding efficacy, the CNS-ORR was 42.6%. As of May 20, 2024, the median progression-free survival (PFS) was 7.7 months, and the median overall survival (OS) was 15.1 months.

- Phase II clinical trial of Utidelone Injection in combination with bevacizumab and etoposide for the treatment of HER2- negative breast cancer with brain metastases (investigator-initiated trial)

  The results of this clinical trial were presented orally at the 2025 ASCO annual meeting. The study was designed to investigate the efficacy and safety of Utidelone in combination with bevacizumab and chemotherapy in the treatment of breast cancer brain metastases with a view to finding new treatments that can control intracranial tumors and prolong survival for this group of patients. A total of 34 patients were enrolled in the study, with a median age of 51. Among them, the median number of prior lines of chemotherapy was 3, 10 patients were

treated with bevacizumab, and 9 patients were treated with local treatment targeting brain metastases. As of December 2, 2024 (10.4 months median follow-up), 64.7% of patients received more than six cycles of treatment. In terms of efficacy, CNS-ORR was 67.6%, and CNS-CBR was 88.2%. The median CNS-PFS was 15 months, while the median overall PFS was six months. In terms of safety, the overall tolerability of this combination treatment regimen was good, with most treatment-emergent adverse events (TEAEs) being grade 1-2, manageable and reversible. Nearly two-thirds of the patients completed more than 6 cycles of treatment. The grade 3-4 TEAEs occurred in the study were limited to peripheral neuropathy and bone marrow suppression, with an incidence rate of less than 10%.

- Phase II clinical trial of Utidelone Injection in combination with bevacizumab for the treatment of HER2- positive breast cancer with brain metastases (investigator-initiated trial)

  The results of this clinical trial were presented as a poster at the 2025 San Antonio Breast Cancer Symposium. The primary objective of the study was to evaluate the efficacy and safety of Utidelone in combination with bevacizumab in the treatment of HER2-positive advanced breast cancer with brain metastases. Between May 2022 and April 2025, 50 evaluable patients were enrolled. In patients who had progressed on prior trastuzumab and TKI (pyrotinib) therapy, with more than half having received previous ADC treatment, the combination of Utidelone plus bevacizumab demonstrated substantial intracranial antitumor activity: the central nervous system objective response rate (CNS-ORR) reached 54.0%, and the intracranial disease control rate (CNS-DCR) was as high as 92.0%. The median overall progression-free survival (PFS) was 8.6 months (95% CI: 7.0-10.2), and the median CNS progression-free survival (CNS-PFS) was 15.1 months (95% CI: 8.2-22.0). The regimen exhibited a favorable safety profile, with most adverse events being mild to moderate (grade 1-2) and overall manageable, and no treatment-related deaths were observed. Notably, this regimen did not incorporate any novel anti-HER2 targeted agents yet still achieved such pronounced efficacy, suggesting that Utidelone possesses excellent blood-brain barrier penetration and exerts synergistic effects in combination with bevacizumab.

- Pivotal phase II clinical trial of Utidelone Injection in combination with bevacizumab for the treatment of lung cancer brain metastasis

  Given Utidelone's performance in aforementioned clinical trials, we have initiated this pivotal Phase II registration clinical trial of Utidelone Injection in combination with bevacizumab for the treatment of lung cancer brain metastases. The study has successfully completed the safety lead-in phase and has now progressed to the expansion phase. Patient enrollment is proceeding smoothly, with encouraging early efficacy signals and a manageable safety profile already observed. Specific data will be available following accrual of a sufficient number of evaluable patients and completion of the planned statistical analysis.

- Pivotal phase II clinical trial of Utidelone Injection in combination with capecitabine for the treatment of breast cancer brain metastasis in the United States

  This study adopts a two-stage design and plans to enroll approximately 120 subjects in total, with the primary endpoint being the central nervous system objective response rate (CNS-ORR). The trial is being conducted collaboratively by nearly 20 leading U.S. cancer centers, including the MD Anderson Cancer Center, the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, City of Hope-Duarte, the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, the University of Colorado Hospital, Augusta University, and the University of California, Los Angeles. During the Reporting Period, we have successfully completed the informed consent and dosing procedures for several patients. This marks the first use of Utidelone Injection in a U.S. patient population, representing an important step in the Company's internationalization strategy.

- Phase II clinical study of Utidelone Injection as first-line treatment for unresectable advanced pancreatic cancer

  Pancreatic cancer is a highly malignant tumor, and the combination regimen with gemcitabine remains its primary clinical treatment approach. However, pancreatic cancer cells are prone to developing resistance to gemcitabine, resulting in suboptimal treatment outcomes. Utidelone has shown significant inhibition of pancreatic cancer cell proliferation and colony formation ability, demonstrating strong antitumor activity in pancreatic cancer models. When used in combination with gemcitabine, Utidelone significantly reduces the IC50 value of gemcitabine, and the combined antitumor activity is superior to the traditional combination of paclitaxel and gemcitabine. As of the date of this announcement, 20 patients with unresectable and locally unfit advanced pancreatic cancer were enrolled in the study, with 11 having completed the first efficacy assessment. Among these, 3 patients achieved partial remission (PR), and 5 patients had stable disease (SD). The objective remission rate (ORR) was 27.27%, and the disease control rate (DCR) was 72.72%. The median overall survival (mOS) was 9.57 months. In terms of safety, most adverse events were grade 1-2. The data demonstrates that Utidelone in combination with gemcitabine offers favorable survival benefits and disease control rates for the first-line treatment of advanced pancreatic cancer patients, and has the potential to address the treatment gap in pancreatic cancer, emerging as a new treatment option. During the Reporting Period, we were also granted an orphan drug designation by the FDA for the treatment of pancreatic cancer with Utidelone.

- Phase II clinical study of Utidelone Injection monotherapy in soft tissue sarcoma

  At the 2025 European Society for Medical Oncology Congress (ESMO 2025), we presented data from a phase II clinical study of Utidelone monotherapy in patients with advanced or metastatic soft tissue sarcoma (STS). From August 19, 2022, to March 3, 2025, a total of 27 patients were enrolled, including 15 with leiomyosarcoma, 3 with dedifferentiated liposarcoma (DDLPS), 3 with epithelioid sarcoma, 2 with angiosarcoma, and 4 with other sarcoma subtypes. Among evaluable patients, 2 (7.4%) achieved partial response (PR), and 19 (70.4%)

achieved stable disease (SD), resulting in an ORR of 7.4% and a DCR of 77.8%. The median PFS was 4.6 months (95% CI: 3.6-5.6), with a 12-month OS rate of 80%. In terms of safety, most of treatment-related adverse events (TRAEs) were grade 1-2 and manageable/reversible, with no treatment-related deaths reported. These results indicate that Utidelone exhibits promising clinical efficacy and a favorable safety profile in patients with advanced or metastatic STS previously treated with anthracyclines and TKIs, positioning it as a potential new treatment option for advanced STS.

- Phase III clinical trial of Utidelone Injection for the treatment of advanced NSCLC in China

  Enrollment in this study has reached nearly half of the planned target. However, in light of evolving competitive dynamics in this indication and slower-than-anticipated patient enrollment, the Company has strategically reprioritized its pipeline. Consequently, enrollment in this study has been temporarily suspended. The decision to restart or terminate the study will be made based on future circumstances.

Utidelone Capsule

During the Reporting Period, the pipeline related to Utidelone Capsule progressed rapidly, as we successfully completed its phase I clinical study in the United States and the phase II clinical study in China, and carried out a number of phase II/III large clinical studies globally.

- Utidelone Capsule phase I clinical trial in China (completed)

  The primary objective of this study, the first clinical study of Utidelone Capsule in China, is to examine the safety profile and tolerability of Utidelone Capsule for Chinese patients with advanced solid tumors, and the secondary objectives include evaluating the efficacy of Utidelone Capsule and its absolute bioavailability compared to Utidelone Injection. During the Reporting Period, the study has been completed, in which patients were treated with Utidelone Capsule monotherapy at starting dose of 50 mg/m^2/d-5day (2 patients), with escalation to 75 mg/m^2/d-5 day and 75 mg/m^2/d-7day (3 patients for each) in a 21-day cycle. No patient experienced dose-limiting toxicity (DLT) and the most common ≥ Grade 3 AE was diarrhea appeared at 75 mg/m^2/d-7day, but recovered within 24 hours after supportive treatment. 75 mg/m^2/d-5day was recommended as monotherapy dose. Population pharmacokinetic (PopPK) modeling analysis further confirmed that the median AUC achieved with Utidelone Capsules at 75 mg/m²/d reaches 80% of the mean/median AUC observed with the approved dose of the Utidelone Injection as specified in the prescribing information. 6 patients were evaluable for efficacy with 3 PR (1 for each for cohort) and 3 SD, with DoT of 2-13 cycles. Most TEAEs were Grade 1/2, no AEs led to death or patient withdrawal. The AUCinf of 30 mg/m^2 Utidelone Injection and 60 mg/m^2 Utidelone Capsule was 2974.82 h*ng/mL and 1870.48 h*ng/mL, respectively, demonstrating a bioavailability F% of 31.8%.

- Phase II clinical trial of Utidelone Capsule in combination with capecitabine for the treatment of advanced breast cancer in China (completed)

  The study is a continuation of the phase I clinical study of Utidelone Capsule in China, evaluating the efficacy, safety and pharmacokinetic profile of Utidelone Capsule combined with capecitabine for patients with advanced metastatic breast cancer. This study enrolled a total of 50 patients, all of whom (100%) had received prior taxane or anthracycline therapy; 86% had visceral metastases, 84% had ≥2 metastatic sites, and 42% had received ≥3 prior lines of antitumor therapy. 96% were HER2-negative breast cancer, with 72% HR-positive/HER2-negative subtype and 24% triple-negative breast cancer. 42 patients (84%) had received prior endocrine therapy, and 35 (70%) had received prior CDK4/6 inhibitor therapy. Among the 44 evaluable patients, 27 achieved PR, of whom 23 had confirmed PR, yielding a confirmed ORR of 52.3% and a DCR of 88.6%. The confirmed ORR in the HER2-negative population was 53.5%. In the 44 patients, the median PFS was 8.25 months, the median duration of response (DoR) was 7.62 months, and the median treatment cycles were 9 (range: 1-21). As of October 8, 2025, 16 patients remained on treatment. These results indicate that Utidelone Capsule plus capecitabine demonstrates efficacy comparable to or better than Utidelone Injection plus capecitabine (as reported in the 2018 ASCO oral presentation: ORR of 49.8%, DCR of 65.8%, median treatment cycles of 6) for the treatment of advanced breast cancer. In terms of safety, compared with Utidelone Injection plus capecitabine, the Utidelone Capsule plus capecitabine regimen substantially reduced the incidence and severity of peripheral neuropathy, with grade 3 events decreasing from 25.1% to 2%, while grade 3 hematologic toxicity remained low at 12%. The incidence of adverse events leading to treatment discontinuation was also markedly lower, decreasing from 29.6% to 4%. In summary, the fully oral dual chemotherapy regimen of Utidelone Capsule plus capecitabine tablets provides comparable or superior therapeutic benefit while improving safety and patient compliance. It eliminates the burden of 5 consecutive days of intravenous infusion, premedication for hypersensitivity prevention, and injection-related adverse reactions associated with intravenous formulations, offering patients a more convenient administration method, enhanced safety profile, and substantial clinical value.



PPS population waterfall plot



PFS Kaplan-Meier curve (PPS population)

- Phase II clinical trial of Utidelone Capsule in combination with capecitabine for the treatment of advanced breast cancer in China (investigator-initiated trial)

  This study is a single-arm, phase II investigator-initiated clinical study designed to enroll patients with recurrent or metastatic HER2-negative breast cancer who had previously received taxane- and/or anthracycline-containing chemotherapy regimens. Participants received combination therapy with Utidelone Capsules plus capecitabine to evaluate efficacy and safety. A total of 39 patients were enrolled. The median age was 56 years; 75.8% of patients had ≥2 metastatic sites, the median number of prior treatment lines was 2, 87.9% had received prior taxane therapy, and 75.8% had received prior anthracycline therapy. Among the 37 evaluable patients, 18 achieved PR, of whom 15 had confirmed PR. The unconfirmed ORR was 48.6%. As of the latest follow-up, 6 patients remained on treatment, including 4 patients who had been on therapy for more than 1 year. The incidence of any ≥grade 3 Utidelone Capsule-related treatment- TRAEs was below 10%. No grade 3 or higher peripheral neuropathy was observed, and no treatment-related deaths occurred.

- Utidelone Capsule phase I clinical trial in the United States (completed)

  The primary objective of this study, the first to enter human clinical studies of Utidelone Capsule worldwide, is to examine the safety profile and tolerability of Utidelone Capsule for patients with advanced solid tumors in the United States, and secondary objectives include evaluating the efficacy and PK behavior of Utidelone Capsule. The study has been completed. Patients were treated with Utidelone Capsule monotherapy. The starting dose was 5-day 25 $mg/m^2/d$ for 2 patients, with planned escalation to 5-day 50, 75, 100 $mg/m^2/d$ and 7-day 70 $mg/m^2/d$ for 2, 6, 3 and 2 patients, respectively in a 21-day cycle. All patients had received prior treatment in advanced settings with maximal 9 lines. Two DLTs of Grade 3 and Grade 4 diarrhea occurred, one at 5-day 100 $mg/m^2/d$ and one at 7-day 70 $mg/m^2/d$. MTD was determined to be 5-day 75 $mg/m^2/d$. 11 patients were evaluated for efficacy with an outcome of 1 CR (ovarian cancer), 1 PR (ovarian cancer), 7 SD (testicular Sertoli cell tumor, NSCLC×2, pancreatic adenocarcinoma×2, appendiceal adenocarcinoma and soft tissue sarcoma), with the longest DoT of 12 cycles. The ORR was 18.2% and the CBR was 81.8%. The most frequent TEAEs were Grade 1/2, including diarrhea, fatigue, nausea, peripheral sensory neuropathy, vomiting, and decreased appetite (≥20% incidence rate), which recovered with supportive treatments. This study demonstrates encouraging anti-tumor activity with manageable safety of Utidelone Capsule in patients with heavily pre-treated advanced solid tumors. The latest research findings have been presented as a poster at the 2025 ASCO annual meeting.



Figure: Waterfall plot of maximum percentage of tumor reduction



Figure: Spider plot of maximum percentage of tumor reduction

- <u>International multi-center phase II/III clinical study of Utidelone Capsule in combination with fluoropyrimidine and platinum for the first-line treatment of locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma</u>

  The phase II study, which is proposed to enroll 78 subjects, is planned to be conducted in China and the United States, with the primary objective of evaluating the safety, efficacy and pharmacokinetic profile of Utidelone Capsule combined with other drugs. The phase III study, which is proposed to enroll 700 subjects, is planned to be conducted in China, the United States, Asia, Europe, and other countries and regions, with the primary endpoint being the overall survival (OS), and the secondary endpoints including progression-free survival (PFS), ORR and safety. The phase II/III clinical IND has been approved by the FDA and CDE, and the patient enrollment is progressing vigorously.

- Phase II/III clinical study of Utidelone Capsule monotherapy for patients with platinum-resistant advanced epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer

  The phase II study is proposed to enroll 72 subjects, with the primary objective of evaluating the safety profile, efficacy, and pharmacokinetic profile of different dosing regimens of Utidelone Capsule monotherapy in the target patients. The phase III study is proposed to enroll 480 subjects to evaluate the efficacy and safety of Utidelone Capsule compared to the chemotherapy selected by researchers for patients with platinum-resistant advanced epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer. The phase II/III clinical IND has been approved by the CDE, and the patient enrollment is progressing vigorously.

- Phase II clinical study of Utidelone Capsule in combination with bevacizumab for patients with platinum-resistant advanced epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer in the United States

  This phase II study consists of a safety lead-in phase and an expansion phase, with a planned enrollment of approximately 70 subjects. The primary objective is to evaluate the safety, efficacy, and pharmacokinetic profile of Utidelone Capsules in combination with bevacizumab in the target patient population. The clinical IND application received FDA approval in November 2025 and is currently in the study initiation and startup phase.

- Phase II clinical study of Utidelone Capsule in combination with fruquintinib capsules for the treatment of platinum-resistant recurrent ovarian cancer

  This study is being conducted at Fudan University Shanghai Cancer Center. It plans to enroll approximately 35 patients, with the primary objectives to evaluate the ORR of Utidelone Capsules in combination with fruquintinib capsules in patients with platinum-resistant recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. To date, more than half of the planned patients have been enrolled. Efficacy evaluation has been completed in 14 patients, with the following results: 1 CR, 8 PR, and 5 cases of SD. This yields an ORR of 64.3% and a DCR of 100%, with a median PFS of 7 months, which indicate favorable overall safety profile. Final data will be available following accrual of a sufficient number of evaluable patients and completion of the planned statistical analysis.

- Phase III clinical study of Utidelone Capsule combined with capecitabine in adjuvant intensive treatment for early TNBC that did not achieve complete pathological remission after neoadjuvant treatment

  Adjuvant chemotherapy options for TNBC patients are very limited. Utidelone Capsule can improve medication compliance and reduce patient's hospital stay, enhance convenience, support long-term treatment, and substantially lowere clinical treatment costs for patients. Meanwhile, Utidelone's previous safety data supports its long-term administration, which is beneficial for long-term adjuvant intensive treatment. The study is planned to enroll 440 patients with early TNBC who had previously received neoadjuvant chemotherapy and had not

achieved complete pathological remission after surgery, in order to evaluate the 3-year invasive disease free survival (IDFS) rate, overall survival (OS) rate and safety profile of Utidelone Capsule in combination with capecitabine compared to the capecitabine monotherapy for adjuvant treatment of early TNBC patients that had not achieved complete pathological remission after neoadjuvant treatment. Currently, the enrollment of the study is progressing vigorously.

- Utidelone antibody drug conjugate

  The Company is building a next-generation antibody-drug conjugate (ADC) technology platform with fully independent intellectual property rights. This platform focuses on systematic innovation around two core elements: a differentiated payload system and linkers. Unlike prevailing ADC products that commonly use widely adopted payloads such as MMAE or Topo I inhibitors, this platform innovatively employs the Company's proprietary Utidelone and other epothilone derivatives as the core toxin molecules, which can be selectively combined with Topo I inhibitors to develop dual-payload or multi-payload ADC drugs. Utidelone and other epothilone derivative payloads belong to the class of epothilone-based microtubule-stabilizing agents. They exhibit potent antitumor activity, excellent cell membrane permeability, potential to overcome P-glycoprotein (P-gp)-mediated multidrug resistance in tumor cells, a well-defined mechanism of action, and a favorable safety profile, conferring significant differentiated competitive advantages in the ADC field.

  Regarding linker selection, the Company has conducted systematic optimization and structural design of the linker moiety. Through site-specific conjugation and structure-based engineering, a higher and more controlled drug-to-antibody ratio (DAR) has been achieved while maintaining excellent in vivo stability. It also enables targeted modulation of the release kinetics of different payloads. A higher DAR is expected to significantly improve the payload delivery efficiency per antibody molecule, thereby enhancing cytotoxic potency against tumor cells while expanding the therapeutic window through optimized pharmacokinetic profiles. This platform is designed to address key clinical challenges associated with traditional ADCs including insufficient efficacy, the emergence of resistance, and safety constraints, providing a more promising therapeutic alternative for patients with solid tumors and refractory malignancies.

  Preclinical studies are currently advancing vigorously, with the goal of reaching the IND-enabling stage in 2026.

2. ***Strategic marketing cooperation***

During the Reporting Period, the cooperation with Qingdao Baheal Medical INC.* (青島百洋醫藥股份有限公司) in terms of marketing service for Utidelone Injection was further strengthened. We are of the opinion that the Group will take this opportunity to integrate resources more efficiently, further expand the market space of its core products, maximize the scientific and commercial value of the Group's technology platform, accelerate the research and development and implementation

of more pipeline projects, and lay a solid foundation for the sustainable development and value creation of the enterprise through cooperation with companies with excellent commercialization capabilities.

3. *Intellectual property*

During the Reporting Period, we successively secured PCT patent grants for oral formulations of Utidelone in Canada and South Korea, and for Utidelone liposomes in Europe. Notably, we obtained a U.S. PCT grant for the genetically engineered microbial strains used in the fermentative production of Utidelone. The molecular structure of Utidelone is highly complex, making efficient large-scale production and industrialization via total chemical synthesis or semi-synthesis exceedingly difficult. Furthermore, chemically synthesized products exhibit significant disparities compared to those produced through microbial fermentation of genetically engineered strains in terms of quality standards, pharmacological properties, production costs, and clinical safety. The patented genetically engineered strain was developed using the Company's proprietary synthetic biology platform, enabling the industrialized production of Utidelone through fermentation processes. As this genetically engineered strain is both the prerequisite and the core starting material for Utidelone production, this patent grant creates a formidable global barrier to entry for generics. Consequently, the entry of generic Utidelone into the market is rendered virtually impossible until the patent expires in 2041.

We have also aggressively expanded our patent strategy through new applications and entries into the national phase, including patents relating to antibody-drug conjugates of Utidelone or its derivatives, PCT patents related to Utidelone cyclodextrin inclusion complex, PCT patents related to Utidelone for the treatment of various solid tumor indications, and albumin-bound Utidelone nanoparticles related PCT patents.

4. *Development Strategies and Business Prospects*

Launching our products worldwide by continuously enhancing our R&D activities

We will further strengthen R&D efforts surrounding our product pipeline, and enhance the commercial value of products through in-house R&D as well as external collaboration:

— Clinical trial of Utidelone Injection:

  In addition to advanced breast cancer, we will also actively advance the clinical progress in respect of other indications, such as breast cancer neoadjuvant, breast cancer and lung cancer brain metastases, and pancreatic cancer. We will continue to boost more indications of Core Product so as to extend our future market prospect.

— Clinical trials of Utidelone Capsule:

As the oral formulation of Utidelone, Utidelone Capsule provides patients with better convenience and adherence, and alleviates patients' economic burden. Based on the excellent data from the completed clinical studies of Utidelone Capsule in China and the U.S., we have exerted much effort in the subsequent phase II/III clinical pipeline of Utidelone Capsule, for which three large-scale studies including the phase III clinical study for strengthened TNBC adjuvant treatment, the phase II/III international multi-center clinical study for advanced gastric cancer, and the phase II/III international multi-center clinical study for advanced ovarian cancer, are vigorously undergoing the enrollment.

— R&D of ADC products:

Given the potential of Utidelone and its derivatives to become a good payload for ADC drugs and our progress in the preliminary explorations of ADC programs, we will use our best efforts to develop the ADC programs with Utidelone and its derivatives as payload drug program and advance it to the clinical stage as soon as possible, so as to further enrich our product portfolio and continuously increase the diversification and competitiveness of the Company's product pipeline.

— Global activities:

Putting great emphasis on accelerating the application and clinical progress of our pipeline in overseas markets, we will consistently push forward programs that have been approved for clinical trials, as well as introduce more clinical programs globally. In addition, we are actively selecting reliable global partners through out-licensing out of China rights or co-development of Utidelone Injection, Capsule and ADC projects. We believe that our strong capabilities of R&D and manufacturing, coupled with our enriched commercial expertise, make us the preferred partner for global biopharmaceutical companies who share our goal of bringing innovative anti-cancer products to patients around the world.

— Satisfying global needs by optimizing our production quality and capacity

We are committed to consolidating our strengths in terms of production and will continue to invest in high-caliber manufacturing equipment and optimal manufacturing environment so as to better satisfy our R&D and production needs while also achieving economies of scale and cost reduction during production. In anticipation of the rapid progress of our overseas clinical trials and commercialization, we will upgrade our production facilities in accordance with cGMP standard to serve as groundwork for the future delivery of our products on a global scale.

— Extending brand recognition and market reach

We will further strengthen the in-depth cooperation with our partner Baheal Medical, consolidate both parties' resources in a more efficient way, and formulate a comprehensive, professional and differentiated academic promotion plan and commercialization development strategy to cover medical institutions in key provinces and cities nationwide, with a view to rapidly enhancing the market recognition and penetration of Utidelone Injection.

— Speeding up technological innovation and commercialization by attracting, cultivating, and retaining top-tier talents

We place a high priority on selecting and retaining talents. To sustain our growth, we will continue to recruit top professionals in R&D, clinical development, and commercialization. We are committed to providing our employees with comprehensive career development and learning opportunities, guidance from veterans, clear career development paths, competitive remuneration, and a collaborative and supportive working environment to achieve a corporate culture that attracts and retains like-minded, top-tier talents.

FINANCIAL REVIEW

Revenue

Total revenue of the Group for the Reporting Period was RMB33.4 million, representing a decrease of 53.5% from that of RMB71.9 million for the year ended December 31, 2024. Such change was mainly due to sales fluctuations caused by the adjustment of the marketing strategy of our product **Utidelone Injection**.

Operating Costs

During the Reporting Period, the cost of sales of the Group was RMB2.6 million, representing a decrease of 73.2% from RMB9.7 million for the year ended December 31, 2024. Such change was mainly due to the decrease in cost of sales resulting from the optimization of the production process of our product **Utidelone Injection** and the sales fluctuations caused by the adjustment of the marketing strategy.

Gross Profit and Gross Profit Margin

As a result of the foregoing factors, the gross profit of the Group decreased by 50.5% from RMB62.2 million for the year ended December 31, 2024 to RMB30.8 million for the year ended December 31, 2025, mainly due to the decrease in operating income and operating costs. The gross profit margin of the Group was 92.2% for the year ended December 31, 2025 as compared to 86.5% for the year ended December 31, 2024. The increase in gross profit margin is attributable to the decrease in cost of sales as a result of the optimization of the production process of the products.

Taxes and Surcharges

During the Reporting Period, our taxes and surcharges remained relatively stable, totaling RMB1.1 million for the year ended December 31, 2025, compared to RMB1.0 million for the year ended December 31, 2024.

Selling Expenses

Our selling expenses decreased by 49.8% from RMB61.9 million for the year ended December 31, 2024 to RMB31.1 million for the year ended December 31, 2025, mainly due to the decrease in selling expenses as the results of our strict control of selling expenses.

Administrative Expenses

Our administrative expenses decreased by 34% from RMB52.3 million for the year ended December 31, 2024 to RMB34.5 million for the year ended December 31, 2025, mainly due to the decrease in our professional services fees.

R&D Expenses

Our R&D expenses decreased by 28.6% from RMB116.3 million for the year ended December 31, 2024 to RMB83 million for the year ended December 31, 2025, mainly due to the decrease in clinical expenditure and technical services expenditure as major clinical programs entered the end stage of enrolment.

Financial Costs

Our finance costs increased by 177.3% from RMB–7.5 million for the year ended December 31, 2024 to RMB5.8 million for the year ended December 31, 2025, primarily due to foreign exchange losses arising from fluctuations in foreign exchange rates.

Non-operating Income

Our non-operating income increased by 2,800.0% from RMB0.1 million for the year ended December 31, 2024 to RMB2.9 million for the year ended December 31, 2025, mainly due to an increase in margin income from the marketing service provider business.

Income Tax Expenses

For the year ended December 31, 2024 and December 31, 2025, we recognized that no income tax expense was incurred.

Net Profit

Due to the above reasons, our loss decreased by RMB12.4 million from RMB143.8 million for the year ended December 31, 2024 to RMB131.4 million for the year ended December 31, 2025.

Key Financial Ratios

The table below sets forth our key financial ratios as of the dates indicated:

	As at December 31, 2025	As at December 31, 2024
Current ratio (times)	**8.3**	8.8
Quick ratio (times)	**7.7**	8.4
Gearing ratio (%)	**14.0%**	13.4%

Notes:

1. Current ratio equals current assets divided by current liabilities as of the same date.

2. Quick ratio equals currents assets less inventories and divided by current liabilities as of the same date.

3. Gearing ratio is calculated by dividing total liabilities by total assets as of the same date.

NET CURRENT ASSETS

Our net current assets decreased by 18% from RMB620.1 million as of December 31, 2024 to RMB508.6 million as of December 31, 2025, which was due to the provision of cash to finance our research and development activities, construction of our research and development and production facilities, purchase of equipment and machinery, and day-to-day operations.

As of December 31, 2025, our current assets amounted to RMB578 million, including monetary funds of RMB456.8 million, accounts receivable of RMB7.2 million, prepayments of RMB3.6 million, other receivables of RMB58.9 million, inventories of RMB45.5 million and other current assets of RMB6.2 million. As of December 31, 2025, our current liabilities amounted to RMB69.4 million, including trade payables of RMB53.8 million, contract liabilities of RMB4.8 million, payroll payable of RMB2.9 million, taxes and fees payable of RMB0.2 million, other payables of RMB6.7 million and non-current liabilities due within one year of RMB1.0 million.

CAPITAL MANAGEMENT

The primary objectives of the Group's capital management are to maintain the Group's stability and growth, safeguard its normal operations and maximise shareholder value. The Group regularly reviews and manages its capital structure and makes timely adjustments in light of changes in operating and market conditions.

LIQUIDITY AND FINANCIAL RESOURCES

As of December 31, 2025, our monetary funds (mainly denominated in U.S. dollars and RMB), financial assets measured at fair value through profit or loss and other non-current financial assets amounted to RMB491.8 million, representing a decrease of 19.1% from RMB607.6 million as at December 31, 2024. The decrease was mainly due to the provision of cash to finance our research and development activities, construction of our research and development and production facilities, purchase of equipment and machinery, and day-to-day operations during the Reporting Period.

SIGNIFICANT INVESTMENTS HELD

As of December 31, 2025, the Group did not make or hold any significant investments (including any investments in investee companies amounting to 5% or more of the total assets of the Company as at December 31, 2025).

CONTINGENT LIABILITIES

As of December 31, 2025, we did not have any contingent liabilities.

CHARGE ON ASSETS

As of December 31, 2025, the Group had no charge on assets.

FOREIGN EXCHANGE EXPOSURE

We are exposed to currency risk primarily through bank deposits and intra-group receivables denominated in foreign currencies. The currency giving rise to such risk is primarily the U.S. dollars. During the Reporting Period, our business was not materially affected by fluctuations in exchange rates.

EMPLOYEES AND REMUNERATION POLICY

Currently, our employees are mainly from the mainland China and Hong Kong. As of December 31, 2025, the Group had a total of 134 employees. Total remuneration costs incurred by the Group amounted to RMB53.1 million for the year ended December 31, 2025, compared with RMB80.5 million for the year ended December 31, 2024.

The Group has a comprehensive remuneration system to ensure that employees receive fair and reasonable salaries and rewards. We strictly abide by relevant national and regional laws and regulations and pay "five social insurances and one housing fund" according to law, including pension insurance, medical insurance, unemployment compensation, work injury insurance, maternity insurance and housing provident fund, so as to ensure employees enjoy social insurance benefits. For outstanding employees, all rewards are filed with the human resources department and serve as an important basis for personal salary increases and promotions. In addition to salary and social protection insurance, we also provide paid annual leave, maternity leave, nursing leave, sick leave, personal leave and other holiday benefits to improve the life quality of employees and enhance their sense of belonging.

In recognition of the contributions of our employees and to motivate them to further boost the development of the Company, employee incentive schemes were approved and adopted in November 2020, January 2021 and January 2022 respectively. For further details, please refer to the paragraph headed "APPENDIX VII — STATUTORY AND GENERAL INFORMATION — D. PRE-IPO EMPLOYEE INCENTIVE SCHEMES" in the Prospectus.

MATERIAL ACQUISITIONS AND DISPOSALS

The Group did not make any significant investments, material acquisitions or disposals of subsidiaries, associates and joint ventures during the Reporting Period.

CORPORATE GOVERNANCE

Compliance with the Corporate Governance Code

The Board is committed to maintaining high corporate governance standards to safeguard the interests of Shareholders and to enhance corporate value and accountability.

The Company has adopted the principles and code provisions of the Corporate Governance Code as the basis of the Company's corporate governance practices.

In the opinion of the Directors, throughout the Reporting Period, the Company has complied with all applicable code provisions set out in the Corporate Governance Code.

The Board will continue to review and monitor the Company's practices with the aim of maintaining high standards of corporate governance.

Compliance with the Model Code for Securities Transactions by Directors

The Company has adopted the Model Code to regulate all dealings by Directors and relevant employees in securities of the Company and other matters covered by the Model Code.

Specific enquiry has been made to all the Directors and they have confirmed that they have complied with the required standards as set out in the Model Code throughout the Reporting Period. No incident of non-compliance of the Model Code by the relevant employees was identified by the Company throughout the Reporting Period.

USE OF NET PROCEEDS FROM THE GLOBAL OFFERING

The Company issued 14,588,000 H Shares with a nominal value of RMB1.00 each at HK$16 per Share, which were listed on the Main Board of the Stock Exchange on October 31, 2024. We received net proceeds (after deduction of underwriting commissions and related costs and expenses) from the Global Offering of approximately HK$195.89 million. There has been no change or delay in the proposed use and expected timetable of the net proceeds disclosed in the section headed "Future Plans and Use of Proceeds" in the Prospectus. The following table sets forth the proposed use and the actual use of the net proceeds as at December 31, 2025:

Proposed use		**Percentage of total net proceeds**	**Allocation of net proceeds** *(HK$ million)*	**Utilized amount during the year ended December 31, 2025** *(HK$ million)*	**Unutilized amount as of December 31, 2025** *(HK$ million)*	**Expected timetable for utilizing the remaining unutilized net proceeds**
(i)	To fund our Core Product, Utidelone Injection	44.9%	87.95	5.57	82.38	
	For funding the phase III clinical trial of Utidelone Injection for breast cancer neoadjuvant in China	9.8%	19.20	1.61	17.59	By the mid of 2026
	For funding the phase III clinical trial of Utidelone Injection for advanced NSCLC in China	11.8%	23.12	0.64	22.48	By the end of 2026
	For funding the phase II (pivotal) clinical trial of Utidelone Injection for lung cancer brain metastasis in China	4.6%	9.01	0.46	8.55	By the end of 2027
	For funding the phase II-III international multicenter clinical trial of Utidelone Injection for advanced NSCLC	5.3%	10.38	0	10.38	By the end of 2027
	For funding the phase III international multi-center clinical trial of Utidelone Injection for advanced breast cancer	3.5%	6.86	0.15	6.71	By the end of 2027
	For funding the phase II (pivotal) study of Utidelone Injection for breast cancer brain metastasis in the United States	9.9%	19.39	2.71	16.68	By the end of 2027
(ii)	To fund the ongoing and planned clinical trials and pre-clinical studies of products besides our Core Product and the investigator-initiated trials for our Core Product	38.9%	76.20	3.91	72.29	

Proposed use		Percentage of total net proceeds	Allocation of net proceeds *(HK$ million)*	Utilized amount during the year ended December 31, 2025 *(HK$ million)*	Unutilized amount as of December 31, 2025 *(HK$ million)*	Expected timetable for utilizing the remaining unutilized net proceeds
	For funding the phase II-III MRCT of Utidelone Capsule for advanced gastric and esophageal cancers	35.8%	70.13	0.67	69.46	By the mid of 2028
	For funding the pivotal study of Utidelone Capsule for solid tumor and advanced breast cancer in China	1.2%	2.35	2.35	0	By the mid of 2026
	For funding the ongoing and planned pre- clinical studies, such as Utidelone nano- injection, Utidelone ADC, BG22, BG18 and BG44, and investigator-initiated trials for our Core Product	1.9%	3.72	0.89	2.83	By the end of 2026
(iii)	To strengthen our domestic commercialization capabilities and construct our global marketing network	3.0%	5.88	0	5.88	By the end of 2026
(iv)	To expand our production capacity	3.2%	6.27	0	6.27	By the end of 2026
(v)	For working capital and for general corporate purposes	10.0%	19.59	3.14	16.45	By the end of 2026
Total		100.0%	195.89	12.62	183.27	

AUDIT COMMITTEE

As of the date of this announcement, the Audit Committee of the Company comprises three independent non-executive Directors, namely Mr. Shiu Shu Ming, Dr. Meng Songdong and Mr. Tang Jin. Mr. Shiu Shu Ming is the chairperson of the Audit Committee and possesses appropriate qualifications as required under Rules 3.10(2) and 3.21 of the Listing Rules.

The Audit Committee has considered and reviewed the accounting principles and practices adopted by the Group and has discussed matters in relation to internal controls, risk management and financial reporting with the management of the Company. The Audit Committee reviewed and considered that the annual financial results for the year ended December 31, 2025 are in compliance with the relevant accounting standards, rules and regulations, and appropriate disclosures have been duly made.

SCOPE OF WORK OF WUYIGE CERTIFIED PUBLIC ACCOUNTANTS LLP

The figures in respect of the Group's consolidated statement of financial position, consolidated statement of profit or loss and other comprehensive income and the related notes thereto for the year ended December 31, 2025 as set out in this announcement have been agreed by the Group's auditor, WUYIGE Certified Public Accountants LLP ("**WUYIGE**"), to the amounts set out in the Group's consolidated financial statements for the year ended December 31, 2025. The work performed by WUYIGE in this respect did not constitute an assurance engagement and consequently no opinion or assurance conclusion has been expressed by WUYIGE on this announcement.

EXTRACT OF THE INDEPENDENT AUDITOR'S REPORT

Independent Auditor's Report on the consolidated financial statements of the Group for the year ended 31 December 2025 containing a qualified opinion is as below:

Qualified Opinion

In our opinion, except for the effects of the matter described in the Basis for Qualified Opinion section of our report, the accompanying financial statements give a true and fair view of the consolidated and parent company financial position of the Company as at 31 December 2025, and of its consolidated and parent company financial performance and cash flows for the year then ended, in accordance with the Accounting Standards for Business Enterprises.

Basis for Qualified Opinion

US$5,000,000 represented an investment in certain non-voting redeemable participating shares of an unlisted fund (the "**Fund**") made by the Company in 2024. Pursuant to the subscription agreement, the investment term was one year, during which the investment was classified as financial assets held for trading. The investment was not redeemed upon maturity in November 2025 and was subsequently reclassified to other receivables. In March 2026, the Company entered into a settlement agreement with the Fund, pursuant to which it was agreed that, upon payment of US$2,000,000 by the Fund, the Company would waive its rights to recover or pursue any form of claim in respect of the remaining balance of US$3,000,000. Accordingly, the Company recognised an allowance for expected credit losses of US$3,000,000 (equivalent to approximately RMB21,086,400) in respect of the above amount. We performed audit procedures including inspection of supporting documentation, examination of bank remittance records, external confirmations, and a review of subsequent events. However, we were unable to obtain sufficient appropriate audit evidence regarding the recoverability of the amount, the appropriateness of the impairment provision, and the potential impact on the financial statements.

We conducted our audit in accordance with the Chinese Standards on Auditing for Certified Public Accountants. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics for Chinese Certified Public Accountants and the independence requirements applicable to public interest entities, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified opinion.

PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES OF THE COMPANY

The H Shares of the Company were first listed on the Stock Exchange on October 31, 2024. During the period from the Listing Date to December 31, 2025, neither the Company nor any of its subsidiaries has purchased, sold or redeemed any of the Company's listed securities (including the sale of treasury shares).

As at December 31, 2025, the Company did not hold any treasury shares (as defined in the Listing Rules).

FINAL DIVIDEND

The Board has resolved not to recommend a final dividend for the year ended December 31, 2025 (2024: Nil).

SIGNIFICANT EVENTS AFTER THE REPORTING PERIOD

Save as disclosed in this announcement, our Group is not aware of any material subsequent events after the Reporting Period relating to the Group's business or financial performance.

PUBLICATION OF ANNUAL RESULTS ANNOUNCEMENT AND ANNUAL REPORT

This announcement is published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.biostar-pharm.com). The annual report of the Company for the Reporting Period will be published on the above websites and will be dispatched to the Shareholders in due course.

APPRECIATION

The Board would like to express its sincere gratitude to our Shareholders and business partners for their continued trust and support, and to our employees for their diligence, dedication, loyalty and integrity.

CONSOLIDATED BALANCE SHEET

(Unless otherwise stated, all amounts are denominated in RMB)

Items	Notes	December 31, 2025	December 31, 2024
Current Assets:			
Monetary funds		**456,766,910.79**	466,636,149.82
Financial assets held for trading			105,989,480.32
Derivative financial assets			
Bills receivable			
Accounts receivable	*V. (I)*	**7,156,522.30**	23,152,252.38
Receivables financing			
Prepayments	*V. (II)*	**3,576,777.59**	67,074,482.41
Other receivables	*V. (III)*	**58,865,263.75**	852,101.37
Among which: Interest receivable			
Dividend receivable			
Inventories		**45,493,637.08**	31,419,170.70
Contract assets			
Assets held for sale			
Non-current assets due within one year			
Other current assets		**6,172,947.85**	4,135,536.05
Total Current Assets		**578,032,059.36**	699,259,173.05
Non-current Assets:			
Debt investments			
Other debt investments			
Long-term receivables			
Long-term equity investments			
Other equity instrument investments			
Other non-current financial assets	*V. (IV)*	**35,000,000.00**	35,000,000.00
Investment properties			
Fixed assets		**72,303,071.28**	66,235,066.00
Construction in progress		**73,441,693.56**	97,489,482.64
Biological assets for production			
Oil and gas assets			
Right-of-use assets		**2,144,837.87**	1,347,721.41
Intangible assets		**12,447,713.05**	12,960,417.42
Development expenditures			
Goodwill			
Long-term deferred expenses			
Deferred income tax assets			
Other non-current assets		**899,381.30**	952,397.30
Total Non-current Assets		**196,236,697.06**	213,985,084.77
Total Assets		**774,268,756.42**	913,244,257.82

Items	Notes	December 31, 2025	December 31, 2024
Current Liabilities:			
Short-term borrowings			
Financial liabilities held for trading			
Derivative financial liabilities			
Bills payable			
Accounts payable	*V. (V)*	**53,822,602.40**	48,331,057.21
Receipts in advance			
Contract liabilities	*V. (VI)*	**4,798,978.29**	4,716,981.13
Employee remuneration payable		**2,880,532.56**	8,379,308.34
Taxes payable		**159,351.30**	381,620.36
Other payables	*V. (VII)*	**6,700,119.66**	13,856,726.75
Among which: Interest payable			
Dividend payable			
Liabilities held for sale			
Non-current liabilities due within one year		**1,047,592.85**	665,219.19
Other current liabilities			2,830,188.68
Total Current Liabilities		**69,409,177.06**	79,161,101.66
Non-current Liabilities:			
Long-term borrowings			
Bonds payable			
Among which: Preference shares			
Perpetual bonds			
Lease liabilities		**927,401.40**	516,517.72
Long-term payables			
Long-term employee remuneration payable			
Provisions			
Deferred income		**118,032.81**	366,156.35
Deferred income tax liabilities			
Other non-current liabilities	*V. (VIII)*	**37,735,849.06**	42,452,830.19
Total Non-current Liabilities		**38,781,283.27**	43,335,504.26
Total Liabilities		**108,190,460.33**	122,496,605.92

Items	*Notes*	**December 31, 2025**	December 31, 2024
Shareholders' Equity:			
Share capital		**364,588,000.00**	364,588,000.00
Other equity instruments			
Among which: Preference shares			
Perpetual bonds			
Capital reserve		**1,307,118,183.19**	1,298,264,271.78
Less: Treasury shares			
Other comprehensive income		**–2,074,444.18**	13,714.48
Special reserve			
Surplus reserve			
Retained earnings		**–1,003,553,442.92**	–872,118,334.36
Total Equity Attributable to Owners of the Parent		**666,078,296.09**	790,747,651.90
Non-controlling interests			
Total Shareholders' Equity		**666,078,296.09**	790,747,651.90
Total Liabilities and Shareholders' Equity		**774,268,756.42**	913,244,257.82

CONSOLIDATED STATEMENT OF PROFIT OR LOSS

(Unless otherwise stated, all amounts are denominated in RMB)

Items	*Notes*	**2025**	2024
I. Operating Revenue	*V. (IX)*	**33,364,260.46**	71,865,551.56
Less: Cost of sales	*V. (IX)*	**2,606,963.38**	9,745,139.98
Taxes and surcharges		**1,086,919.04**	1,035,776.87
Selling expenses	*V. (X)*	**31,100,158.31**	61,927,091.72
Administrative expenses	*V. (XI)*	**34,523,783.28**	52,337,637.64
Research and development expenses	*V. (XII)*	**82,993,063.22**	116,291,717.95
Finance costs	*V. (XIII)*	**5,807,324.63**	–7,475,431.61
Among which: Interest expenses		**46,310.02**	55,605.55
Interest income		**4,465,928.17**	2,043,623.96
Add: Other income		**1,595,463.67**	2,212,848.28
Investment income (losses are presented with "–")		**11,873,556.57**	16,302,890.35
Among which: Investment income from associates and joint ventures			
Gains on derecognition of financial assets measured at amortised cost			
Net gains on hedge of open position (losses are presented with "–")			
Gains on changes in fair value (losses are presented with "–")		**–47,480.32**	492,737.45
Impairment losses on credit assets(losses are presented with "–")		**–20,652,179.39**	–293,512.51
Impairment losses on assets (losses are presented with "–")		**–2,362,553.64**	–288,474.57
Gains on disposal of assets (losses are presented with "–")			
II. Operating Profit (loss is presented with "–")		**–134,347,144.51**	–143,569,891.99
Add: Non-operating income		**2,938,519.06**	140,600.05
Less: Non-operating expenses		**26,483.11**	347,226.40
III. Total Profit (total loss is presented with "–")		**–131,435,108.56**	–143,776,518.34
Less: Income tax expense			
IV. Net Profit (net loss is presented with "–")		**–131,435,108.56**	–143,776,518.34
(I) Classified by continuity of operations:			
1.Net profit from continuing operations (net loss is presented with "–")		**–131,435,108.56**	–143,776,518.34
2.Net profit from discontinued operations (net loss is presented with "–")			
(II) Classified by ownership:			
1.Net profit attributable to owners of the parent (net loss is presented with "–")		**–131,435,108.56**	–143,776,518.34
2.Net profit attributable to non-controlling interests (net loss is presented with "–")			

Items	*Notes*	**2025**	2024
V. Other Comprehensive Income, Net of Tax		**–2,088,158.66**	363,630.19
(I) Other Comprehensive Income Attributable to Owners of the Parent, Net of Tax		**–2,088,158.66**	363,630.19
1.Other comprehensive income that will not be reclassified to profit or loss			
(1) Re-measurement of defined benefit plans			
(2) Other comprehensive income not reclassified to profit or loss under equity method			
(3) Changes in fair value of other equity instrument investments			
(4) Changes in fair value of the Company's own credit risk			
2.Other comprehensive income that will be reclassified to profit or loss		**–2,088,158.66**	363,630.19
(1) Other comprehensive income reclassified to profit or loss under equity method			
(2) Changes in fair value of other debt investments			
(3) Amounts reclassified to other comprehensive income on reclassification of financial assets			
(4) Impairment provision for other debt investments			
(5) Cash flow hedge reserve (effective portion of cash flow hedge gains or losses)			
(6) Foreign currency translation differences for foreign financial statements		**–2,088,158.66**	363,630.19
(7) Others			
(II) Other Comprehensive Income Attributable to Non-controlling Interests, Net of Tax			
VI. Total Comprehensive Income		**–133,523,267.22**	–143,412,888.15
(I) Total Comprehensive Income Attributable to Owners of the Parent		**–133,523,267.22**	–143,412,888.15
(II) Total Comprehensive Income Attributable to Non-controlling Interests			
VII. Earnings Per Share			
(I) Basic Earnings Per Share	*IX. (I)*	**–0.36**	–0.41
(II) Diluted Earnings Per Share	*IX. (I)*	**–0.36**	–0.41

The accompanying notes to the financial statements form an integral part of these financial statements.

NOTES TO THE FINANCIAL STATEMENTS

(Unless otherwise stated, all amounts are denominated in RMB)

I. GENERAL INFORMATION OF THE COMPANY

(I) Place of Registration and Head Office Address

Beijing Biostar Pharmaceuticals Co., Ltd. (hereinafter referred to as the "Company", and collectively referred to as the "Group" when including its subsidiaries) is a joint stock company registered in Beijing, the People's Republic of China, established on July 11, 2002. The Company was listed on The Stock Exchange of Hong Kong Limited (HKEX) in October 2024. It currently holds a business license issued by the Market Supervision Administration of Beijing Economic-Technological Development Area with the Unified Social Credit Code 9111010874157874XP. The registered capital of the Company is RMB 364.588 million. The legal representative is Tang Li. Both the place of registration and the head office address of the Company are Room 1202B, 12/F, Building 3, No. 22 Ronghua Middle Road, Beijing Economic-Technological Development Area, Beijing.

(II) Principal Business Activities Actually Engaged in by the Company

The Group is mainly engaged in the R&D, production and sales of innovative drugs. The Group's products and pipeline mainly include Utidelone Injection, Utidelone Capsules, Utidelone Nano-formulation, Utidelone Antibody-Drug Conjugate (ADC), BG22, BG18 and BG44. The Group's products are mainly used for the treatment of recurrent or metastatic breast cancer, neoadjuvant therapy for human epidermal growth factor receptor 2 (HER2)-negative breast cancer, advanced non-small cell lung cancer (NSCLC), solid tumors, brain metastases of breast cancer, brain metastases of lung cancer and other brain tumor indications. The Group mainly operates in the domestic market.

(III) Scope of Consolidated Financial Statements

The subsidiaries included in the consolidation scope for the reporting period are as follows:

No.	Name of Subsidiary	Level
1	Chengdu Biostar Pharmaceuticals Co., Ltd.	2
2	Biostar Pharma,Inc.	2
3	SynBio Pharma (Hong Kong)Limited	2

(IV) Approver and Approval Date of the Financial Statements

These financial statements were approved for issuance by the Company's board of directors on March 30, 2026.

II. BASIS OF PREPARATION OF THE FINANCIAL STATEMENTS

(I) Basis of Preparation

Previously, the Group prepared its financial statements for the purpose of disclosure on the HKEX in accordance with Hong Kong Financial Reporting Standards ("HKFRSs"). Pursuant to the Consultation Conclusion on Acceptance of Mainland Accounting and Auditing Standards and Appointment of Mainland Auditors for PRC Incorporated Companies Listed in Hong Kong issued by the HKEX in December 2010, commencing from the

current financial year, the Group has resolved to prepare its financial statements for disclosure on the HKEX in accordance with the Accounting Standards for Business Enterprises and relevant regulations promulgated by the Ministry of Finance of the People's Republic of China (the "MOF").

The financial statements of the Group have been prepared on a going concern basis, in accordance with the Accounting Standards for Business Enterprises — Basic Standard and specific accounting standards and other relevant regulations promulgated by the MOF (hereinafter referred to as the "Accounting Standards for Business Enterprises"), based on actual transactions and events that have occurred, and applying the significant accounting policies and accounting estimates formulated by the Group. In addition, the Group has disclosed relevant financial information in compliance with the Companies Ordinance of Hong Kong and the Listing Rules of the HKEX.

(II) Going Concern

In preparing the financial statements, the Group has comprehensively evaluated its ability to continue as a going concern for the 12 months from the end of the reporting period. The Group is capable of continuing as a going concern for at least 12 months from the end of the reporting period, with no material events affecting its going concern ability. Accordingly, the preparation of the financial statements on a going concern basis is considered appropriate.

III. SIGNIFICANT ACCOUNTING POLICIES AND ACCOUNTING ESTIMATES

(I) Statement of Compliance with Accounting Standards for Business Enterprises

The financial statements prepared by the Group comply with the requirements of the Accounting Standards for Business Enterprises, and present fairly and completely the financial position of the Group as at December 31, 2025, the operating results and cash flows for the year ended December 31, 2025, and other relevant information.

(II) Accounting Period

The Group's accounting year is the calendar year, i.e., from 1 January to 31 December of each year.

(III) Operating Cycle

The Group adopts twelve months in a year as its normal operating cycle, and uses the operating cycle as the criterion for classifying the liquidity of assets and liabilities.

(IV) Functional Currency

Renminbi ("RMB") is the currency of the primary economic environment in which the Group and its domestic subsidiaries operate. The Group and its domestic subsidiaries adopt RMB as their functional currency. The Group's overseas subsidiaries determine their functional currencies as United States dollars and Hong Kong dollars respectively according to the currency of the primary economic environment in which they operate. The currency used by the Group in preparing these financial statements is RMB.

(V) Changes in Significant Accounting Policies and Changes in Accounting Estimates

1. *Changes in Significant Accounting Policies*

To reflect the fluctuations in inventory costs more objectively and timely, better align with the current operating model, improve the accuracy and comparability of cost accounting treatments and facilitate management decision-making, approved by the directors, the Group has changed the inventory issuance valuation method from the first-in, first-out method to the weighted average method with effect from January 1, 2025. Taking into account factors such as a wide variety of inventories, frequent receipts and issuances, rapid inventory turnover and stable prices of finished goods, in accordance with the provisions of Accounting Standard for Business Enterprises No. 28 — Changes in Accounting Policies and Accounting Estimates and Correction of Errors, as it is impracticable to determine the cumulative effect of this change in accounting policy for prior periods, the prospective application method is adopted for this change in accounting policy, which does not involve retrospective adjustment to the financial statements of prior years.

2. *Changes in Significant Accounting Estimates*

None.

IV. TAXES

(I) Principal Taxes and Tax Rates

Tax	Tax Base	Tax Rate
Mainland China		
— Value-Added Tax	Sales revenue, taxable services	13%, 6%
— Urban Maintenance and Construction Tax	Actual paid circulating taxes	7%
— Education Surcharge	Actual paid circulating taxes	3%
— Local Education Surcharge	Actual paid circulating taxes	2%
— Property Tax	Taxable value of property	1.2%
— Corporate Income Tax	Taxable income	15%
Hong Kong Profits Tax	Assessable profit	Note 1
United States Profits Tax	Taxable income	Note 2

Note 1: On March 21, 2018, the Legislative Council of Hong Kong passed the Inland Revenue (Amendment) (No. 7) Bill 2017, introducing a two-tier profits tax rate system. The Bill was signed into law on March 28, 2018 and commenced operation the next day. Under the two-tier system, the first HK$2 million of assessable profits of a qualifying corporation is taxed at 8.25%, and profits in excess of HK$2 million are taxed at 16.5%. The Group's Hong Kong subsidiaries applied the two-tier profits tax rate system for the year. As there was no assessable profit for the year, no Hong Kong profits tax was provided for.

Note 2: The Group's U.S. subsidiary is incorporated in California, United States, and is subject to the tax rate prescribed by the local jurisdiction. The effective income tax rate for the year was 21%. As there was no taxable income for the year, no U.S. corporate income tax was provided for.

(II) Significant Tax Incentives and Approvals

Pursuant to the Enterprise Income Tax Law and relevant regulations, enterprises with High and New Technology Enterprise (''HNTE'') qualification are entitled to a preferential CIT rate of 15%. The Company obtained the HNTE certificate on October 29, 2024, valid for a period of three years. The Company enjoyed the 15% preferential CIT rate for the years 2024 and 2025.

Pursuant to the Announcement of the Ministry of Finance, the State Taxation Administration and the National Development and Reform Commission on Extending the Enterprise Income Tax Policy for the Western Development (Announcement No. 23 of 2020 issued by the Ministry of Finance), from January 1, 2021 to December 31, 2030, enterprise income tax is levied at a reduced rate of 15% on encouraged industrial enterprises located in the western region. An ''encouraged industrial enterprise'' refers to an enterprise whose main business is the industrial projects specified in the Catalogue of Encouraged Industries in the Western Region and whose main business income accounts for more than 60% of the total enterprise income. For the years 2024 and 2025, the Group's subsidiaries in China applied the 15% CIT rate under the Western Development Tax Incentive.

V. Notes to Important Items of the Combined Financial Statements

(I) Accounts Receivable

1. *Disclosure by Ageing*

Ageing	**Balance at End of Period**	Balance at Beginning of Period
Within 1 year (inclusive)	**6,510,644.00**	23,753,545.88
Of which: 0–3 months	**5,603,444.00**	16,753,822.68
3–12 months	**907,200.00**	6,999,723.20
1–2 years	**814,800.00**	
Sub-total	**7,325,444.00**	23,753,545.88
Less: Provision for bad debts	**168,921.70**	601,293.50
Total	**7,156,522.30**	23,152,252.38

2. ***Disclosure by Classification of Bad Debt Provision Methods***

Category	**Balance at End of Period**				**Carrying Value**
	Carrying Balance		**Provision for Bad Debts**		
	Amount	***Proportion (%)***	***Amount***	***Provision Rate (%)***	
Accounts receivable with provision for bad debts individually assessed					
Accounts receivable with provision for bad debts assessed collectively	7,325,444.00	100.00	168,921.70	2.31	7,156,522.30
Of which:					
Portfolio 1: Ageing portfolio	7,325,444.00	100.00	168,921.70	2.31	7,156,522.30
Portfolio 2: Other portfolios					
Total	7,325,444.00	100.00	168,921.70	2.31	7,156,522.30

Category	Balance at Beginning of Period				Carrying Value
	Carrying Balance		Provision for Bad Debts		
	Amount	*Proportion (%)*	*Amount*	*Provision Rate (%)*	
Accounts receivable with provision for bad debts individually assessed					
Accounts receivable with provision for bad debts assessed collectively	23,753,545.88	100.00	601,293.50	2.53	23,152,252.38
Of which:					
Portfolio 1: Ageing portfolio	23,753,545.88	100.00	601,293.50	2.53	23,152,252.38
Portfolio 2: Other portfolios					
Total	23,753,545.88	100.00	601,293.50	2.53	23,152,252.38

(II) Prepayments

1. ***Prepayments by Ageing***

Ageing	**Balance at End of Period**		Balance at Beginning of Period	
	Amount	***Proportion (%)***	*Amount*	*Proportion (%)*
Within 1 year	**2,374,096.08**	**66.38**	65,329,749.82	97.40
1–2 years	**761,781.96**	**21.30**	1,714,450.54	2.56
2–3 years	**431,428.33**	**12.06**	20,281.83	0.03
Over 3 years	**9,471.22**	**0.26**	10,000.22	0.01
Total	**3,576,777.59**	**100.00**	67,074,482.41	100.00

(III) Other Receivables

Item	Balance at End of Period	Balance at Beginning of Period
Interest receivable		
Dividend receivable		
Other receivables	**58,865,263.75**	852,101.37
Total	**58,865,263.75**	852,101.37

1. ***Interest Receivable***

None.

2. ***Dividend Receivable***

None.

3. ***Other Receivables***

(1) *Disclosure by Ageing*

Ageing	Balance at End of Period	Balance at Beginning of Period
Within 1 year (inclusive)	**79,923,781.67**	840,394.43
1–2 years	**31,203.77**	16,877.44
Sub-total	**79,954,985.44**	857,271.87
Less: Provision for bad debts	**21,089,721.69**	5,170.50
Total	**58,865,263.75**	852,101.37

(2) *Disclosure by Nature of Amounts*

Nature of Amounts	Balance at End of Period	Balance at Beginning of Period
Unredeemed investment proceeds upon maturity *(note 1)*	**35,144,000.00**	
Current accounts *(note 2)*	**35,144,000.00**	
Overdue prepayment for equipment procurement *(note 3)*	**9,212,844.00**	
Patient compensation payable	**215,717.00**	516,347.46
Social insurance and housing fund advanced on behalf	**198,272.55**	292,076.77
Utilities advanced	**31,203.77**	32,089.77
Staff loans	**8,948.12**	16,757.87
Sub-total	**79,954,985.44**	857,271.87
Less: Provision for bad debts	**21,089,721.69**	5,170.50
Total	**58,865,263.75**	852,101.37

Note 1: As at December 31, 2025, the Group's receivables from Entity 1 (an unlisted fund) amounted to US$5,000,000. Of which, US$5,000,000 represented investment in certain non-voting redeemable participating shares of Entity 1 made by Biostar Pharma, Inc., a wholly-owned subsidiary of the Group, in 2024. Pursuant to the subscription letter, the investment period was one year, during which it was presented as "financial assets held for trading". The fund investment was not redeemed upon maturity in November 2025, and was subsequently reclassified to "other receivables". In March 2026, Biostar Pharma, Inc. entered into a settlement agreement with Entity 1, pursuant to which it was agreed that upon the payment of US$2,000,000 by Entity 1, Biostar Pharma, Inc. shall waive its rights to demand the repayment of or to initiate any form of claims against the remaining balance of US$3,000,000. Accordingly, the Group has made a bad debt provision for US$3,000,000 (equivalent to approximately RMB21,086,400) in respect of the waived portion.

Note 2: The other receivables have been fully settled in March 2026.

Note 3: The other receivables have been fully settled in March 2026.

(IV) Other Non-current Financial Assets

Category	**Balance at End of Period**	Balance at Beginning of Period
Hangzhou Gongchu Biotechnology Co., Ltd	**35,000,000.00**	35,000,000.00
Total	**35,000,000.00**	35,000,000.00

Note: On December 20, 2024, the Group acquired 4.7619% equity interest in Hangzhou Gongchu Biotechnology Co., Ltd, a private limited company incorporated in the PRC with no quoted market price, for RMB 35,000,000. Hangzhou Gongchu is principally engaged in the research and development, production and sales of innovative drugs.

(V) Accounts Payable

1. ***Classification by Ageing***

Item	**Balance at End of Period**	Balance at Beginning of Period
Within 1 year (inclusive)	**33,551,421.68**	46,223,354.02
Over 1 year	**20,271,180.72**	2,107,703.19
Total	**53,822,602.40**	48,331,057.21

(VI) Contract Liabilities

Item	Balance at End of Period	Balance at Beginning of Period
Exclusive marketing rights	**4,716,981.13**	4,716,981.13
Sales of product	**81,997.16**	
Total	**4,798,978.29**	4,716,981.13

(VII) Other Payables

Item	Balance at End of Period	Balance at Beginning of Period
Interest payable		
Dividend payable		
Other payables	**6,700,119.66**	13,856,726.75
Total	**6,700,119.66**	13,856,726.75

Other Payables by Nature of Amounts

Item	Balance at End of Period	Balance at Beginning of Period
Deposits	**5,630,000.00**	8,003,520.00
Payable government grants	**1,000,000.00**	1,000,000.00
Staff advances	**70,119.66**	1,403,206.75
Service fees to intermediaries		3,450,000.00
Total	**6,700,119.66**	13,856,726.75

(VIII) Other Non-current Liabilities

Item	Balance at End of Period	Balance at Beginning of Period
Contract liabilities due after more than one year (exclusive marketing rights)	**37,735,849.06**	42,452,830.19
Total	**37,735,849.06**	42,452,830.19

(IX) Operating Revenue and Cost of Sales

1. *Operating Revenue and Cost of Sales*

Item	Current Period		Previous Period	
	Revenue	**Cost**	Revenue	Cost
Main business	**28,647,279.33**	**2,606,963.38**	71,865,551.56	9,745,139.98
Other business	**4,716,981.13**			
Total	**33,364,260.46**	**2,606,963.38**	71,865,551.56	9,745,139.98

2. *Breakdown of Operating Revenue and Cost of Sales*

Revenue Classification	Chengdu Biostar Pharmaceuticals Co., Ltd. Operating Revenue	Cost of Sales
By operating region	33,364,260.46	2,606,963.38
Of which: Chinese Mainland	33,364,260.46	2,606,963.38
Other regions		
By business category	33,364,260.46	2,606,963.38
Of which: Goods sales	28,647,279.33	2,606,963.38
Exclusive marketing rights	4,716,981.13	
By contract type	33,364,260.46	2,606,963.38
Of which: Goods sales contracts	28,647,279.33	2,606,963.38
Service contracts	4,716,981.13	
By timing of transfer of goods	33,364,260.46	2,606,963.38
Of which: Performance over time	4,716,981.13	
Performance at a point in time	28,647,279.33	2,606,963.38
Total	33,364,260.46	2,606,963.38

(X) Selling Expenses

Item	Current Period	Previous Period
Marketing promotion expenses	**23,720,142.94**	28,335,026.94
Employee compensation	**4,320,456.84**	26,572,146.58
Share-based compensation	**2,198,374.85**	1,073,047.67
Business entertainment expenses	**248,109.74**	2,727,749.51
Transportation expenses	**205,704.99**	921,622.05
Travel expenses	**203,415.23**	1,768,831.63
Service fees to intermediaries	**121,236.15**	
Communication expenses	**43,819.93**	463,540.45
Office expenses	**19,872.96**	25,408.69
Depreciation expenses	**18,979.64**	28,510.74
Rental expenses		5,000.00
Others	**45.04**	6,207.46
Total	**31,100,158.31**	61,927,091.72

(XI) Administrative Expenses

Item	Current Period	Previous Period
Employee compensation	**14,195,565.28**	13,559,749.86
Service fees to intermediaries	**8,632,537.43**	4,558,048.31
Share-based compensation	**3,422,608.70**	4,412,093.00
Depreciation expenses	**1,945,518.81**	1,795,912.14
Travel and transportation expenses	**1,233,771.79**	451,834.40
Office expenses	**883,341.69**	1,149,579.73
IPO-related expenses	**781,063.74**	24,432,537.47
Legal costs	**676,319.94**	4,778.00
Property management fees	**519,922.86**	173,307.62
Directors' emoluments	**450,000.00**	450,000.00
Water, electricity and gas expenses	**156,621.82**	36,758.04
Business entertainment expenses	**54,151.22**	65,716.54
Amortisation of intangible assets	**35,685.00**	35,685.00
Motor vehicle expenses	**20,537.81**	33,757.88
Communication expenses	**17,695.59**	15,175.98
Repair and maintenance expenses	**17,689.35**	66,679.29
Technical service fees		180,210.64
Others	**1,480,752.26**	915,813.74
Total	**34,523,783.29**	52,337,637.64

(XII) Research and Development Expenses

Item	Current Period	Previous Period
Clinical expenses	**37,724,310.79**	63,455,783.39
Staff costs	**20,099,321.86**	24,962,868.36
Technical service fees	**14,609,714.99**	15,497,653.49
Amortisation of share-based compensation	**3,213,888.68**	2,628,133.75
Depreciation and amortisation	**3,801,104.82**	2,623,270.33
Materials consumed	**–175,909.58**	1,511,847.59
Travel and transportation expenses	**1,293,241.51**	1,125,275.43
Amortisation of water, electricity and gas expenses	**747,220.48**	1,040,589.93
Labour service fees		782,919.65
Patent application and maintenance fees	**620,295.47**	493,960.46
Asset rental and property management fees	**217,697.29**	930,664.04
Office expenses	**346,339.22**	787,517.58
Others	**495,837.69**	451,233.95
Total	**82,993,063.22**	116,291,717.95

(XIII) Finance Costs

Item	Current Period	Previous Period
Interest expenses	**46,310.02**	55,605.55
Less: Interest income	**4,465,928.17**	2,043,623.96
Exchange losses	**11,688,185.43**	
Less: Exchange gains	**1,509,740.81**	5,541,793.17
Bank charges	**48,498.16**	54,379.97
Other expenses		
Total	**5,807,324.63**	–7,475,431.61

VI. COMMITMENTS AND CONTINGENCIES

(I) Commitments

Capital Commitments

Commitments for the acquisition and construction of non-current assets contracted for but not recognised in the financial statements are as follows:

Item	Balance at End of Period	Balance at Beginning of Period
Commitments for the acquisition and construction of non-current assets contracted for but not recognised in the financial statements	**1,907,220.00**	3,780,199.50
Total	**1,907,220.00**	3,780,199.50

(II) Contingencies

As at December 31, 2025, there were no material contingencies for the Group.

VII. EVENTS AFTER THE BALANCE SHEET DATE

(I) Material Non-adjusting Events

None.

(II) Profit Appropriation

None.

(III) Sales Returns

None.

(IV) Other Explanations of Events After the Balance Sheet Date

VIII. OTHER MATERIAL EVENTS

(I) Prior Period Accounting Errors

None.

(II) Annuity Plan

None.

(III) Discontinued Operations

None.

(IV) Segment Reporting

1. *Basis for Determination of Segment Reporting and Accounting Policies*

The Group manages its operations on an integrated basis, consistent with the internal reporting to the Group's highest executive management (the chief operating decision maker) for the purposes of resource allocation and performance assessment. The Group determines its reportable segments based on the types of products provided. The directors of the Company have determined that the Group has only one operating and reportable segment, being the research and development, manufacture and sales of innovative drugs. As this is the Group's only operating segment, no segment information is required to be presented other than disclosures for the entity as a whole.

As the Group's revenue and operating loss are mainly derived from operations in China, and all its non-current assets and capital expenditures are located/incurred in China, no geographical information is required to be presented.

2. *Major Customer Information*

Revenue from customers accounting for over 10% of the Group's total revenue for the respective years is as follows:

Item	**2025**	2024
Customer A	**3,845,878.42**	3,932,053.60

IX. SUPPLEMENTARY INFORMATION

(I) Return on Net Assets and Earnings Per Share

Profit for the Reporting Period	**Weighted Average Return on Net Assets (%)**		**Earnings Per Share**			
			Basic Earnings Per Share		**Diluted Earnings Per Share**	
	Current Period	Previous Period	**Current Period**	Previous Period	**Current Period**	Previous Period
Net profit attributable to ordinary shareholders of the Company	**–17.96**	–20.69	**–0.36**	–0.41	**–0.36**	–0.41
Net profit attributable to ordinary shareholders of the Company after deducting non-recurring gains and losses	**–18.36**	–20.66	**–0.37**	–0.41	**–0.37**	–0.41

"2024" or "Corresponding Period"	the year ended December 31, 2024
"2025" or "Reporting Period"	the year ended December 31, 2025
"Audit Committee"	the audit committee of the Board
"Board"	the board of Directors
"China" or "PRC"	the People's Republic of China, except where the context requires otherwise and for the purposes of this announcement only, excluding Hong Kong, the Macau Special Administrative Region of the People's Republic of China and Taiwan
"Company"	Beijing Biostar Pharmaceuticals Co., Ltd. (北京華昊中天生物醫藥股份有限公司), a limited liability company incorporated in the People's Republic of China, the shares of which are listed on the Main Board of the Stock Exchange (Stock Code: 2563)
"Corporate Governance Code"	the Corporate Governance Code set out in Appendix C1 to the Listing Rules
"Director(s)"	the director(s) of the Company
"Global Offering"	the offering of the Company's Shares as described in the Prospectus
"Group", "our", "our Group", "we" or "us"	The Company and its subsidiaries
"HKD" or "HK$"	Hong Kong dollars, the lawful currency of Hong Kong
"Hong Kong"	the Hong Kong Special Administrative Region of the People's Republic of China
"Listing"	the listing of the Shares on the Main Board of the Stock Exchange, which occurred on the Listing Date
"Listing Date"	October 31, 2024, the date on which the Shares are listed on the Main Board of the Stock Exchange
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange, as amended, supplemented or otherwise modified from time to time

"Main Board"	the stock exchange (excluding the options market) operated by the Stock Exchange which is independent from and operates in parallel with GEM of the Stock Exchange
"Model Code"	the Model Code for Securities Transactions by Directors of Listed Issuers set out in Appendix C3 to the Listing Rules
"Prospectus"	the prospectus dated October 23, 2024 issued by the Company
"RMB"	Renminbi, the lawful currency of China
"Share(s)"	ordinary share(s) in the share capital of the Company with a nominal value of RMB1.00 each, comprising the unlisted shares and H shares
"Shareholder(s)"	holder(s) of the Share(s)
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"treasury shares"	has the meaning ascribed thereto in the Listing Rules
"U.S."	the United States of America
"USD" or "US$"	United States dollars, the lawful currency of the United States of America

By order of the Board
Beijing Biostar Pharmaceuticals Co., Ltd.
Dr. Tang Li
Chairperson, Executive Director, Chief Scientific Officer and Chief Marketing Officer

Beijing, the PRC, March 30, 2026

As at the date of this announcement, the Board comprises (i) Dr. Tang Li, Dr. Qiu Rongguo, Mr. Zhang Cheng and Dr. Guan Jin as executive Directors; (ii) Mr. Tang Jin and Ms. Dai Xuefen as non-executive Directors; and (iii) Dr. Meng Songdong, Mr. Shiu Shu Ming and Dr. Ye Chengang as independent non-executive Directors.